Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia Sells 25,000 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CFO Sandip Kapadia sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total value of $1,004,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Harmony Biosciences Stock Performance

Shares of HRMY traded down $0.65 during mid-day trading on Thursday, hitting $38.01. 961,233 shares of the company’s stock were exchanged, compared to its average volume of 581,495. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The stock’s 50-day simple moving average is $34.66 and its 200-day simple moving average is $35.05. The firm has a market cap of $2.17 billion, a price-to-earnings ratio of 18.01, a price-to-earnings-growth ratio of 0.53 and a beta of 0.78. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, October 29th. The company reported $0.79 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The business had revenue of $186.00 million for the quarter, compared to analyst estimates of $184.07 million. During the same quarter last year, the business posted $0.63 EPS. The firm’s revenue for the quarter was up 16.0% on a year-over-year basis. On average, equities research analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on HRMY. Cantor Fitzgerald boosted their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 30th. HC Wainwright restated a “buy” rating and issued a $75.00 price objective on shares of Harmony Biosciences in a research report on Thursday, January 16th. Raymond James restated an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a research report on Thursday, October 10th. Mizuho upped their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research report on Thursday, October 10th. Finally, Oppenheimer reiterated an “outperform” rating and set a $59.00 target price (up previously from $56.00) on shares of Harmony Biosciences in a research report on Wednesday, October 30th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Harmony Biosciences presently has a consensus rating of “Buy” and an average target price of $55.00.

Hedge Funds Weigh In On Harmony Biosciences

A number of hedge funds have recently bought and sold shares of HRMY. Pacer Advisors Inc. grew its holdings in shares of Harmony Biosciences by 18.2% during the fourth quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock valued at $78,452,000 after buying an additional 351,582 shares during the last quarter. Marshall Wace LLP grew its holdings in shares of Harmony Biosciences by 145.4% during the second quarter. Marshall Wace LLP now owns 305,612 shares of the company’s stock valued at $9,220,000 after buying an additional 181,092 shares during the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Harmony Biosciences by 27.1% during the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after buying an additional 140,690 shares during the last quarter. HealthInvest Partners AB grew its holdings in shares of Harmony Biosciences by 335.2% during the third quarter. HealthInvest Partners AB now owns 151,875 shares of the company’s stock valued at $6,075,000 after buying an additional 116,975 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in shares of Harmony Biosciences by 13.3% during the second quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock valued at $28,871,000 after buying an additional 112,197 shares during the last quarter. Institutional investors own 86.23% of the company’s stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.